An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor

Archives of Pathology and Laboratory Medicine

Volumn 123, Issue 6, 1999, Pages 508-513

  Volk, Emily E ^a   Domen, Ronald E ^a,b   Smith, Martin L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BLOOD DONOR; CLINICAL PROTOCOL; GRANULOPOIESIS; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; MONEY; RECIPIENT; REGISTER; RISK BENEFIT ANALYSIS; SIDE EFFECT; VOLUNTEER;

CLINICAL APPROACH/SOURCE; COMPENSATION; HEALTH CARE AND PUBLIC HEALTH; NONTHERAPEUTIC RESEARCH;

BLOOD DONORS; COMPENSATION AND REDRESS; ETHICS, MEDICAL; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKAPHERESIS; NONTHERAPEUTIC HUMAN EXPERIMENTATION; REGISTRIES; RISK ASSESSMENT;

EID: 0033022652     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kendrick DB. Blood Program in World War II. Washington, DC: Office of the Surgeon General, Department of the Army; 1989.
2. Gordeuk VR, Brittenham CM, Bravo J, Hughes MA, Keating LJ. Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion. 1990;30:239-245.
3. Vengelen-Tyler V, ed. Technical Manual. 12th ed. Bethesda, Md: American Association of Blood Banks; 1996.
4. Anderlini P, Przepiorka D, Champlin R, Korbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood. 1996;88:2819-2825.
5. Tomita D, Petrarca M, Paine T, et al. Effect of a single dose of pegylated human recombinant megakaryocyte growth and development factor (PEG-r-HuMGDF) on platelet counts: implications for platelet apheresis [abstract]. Transfusion. 1997;37(suppl):2S.
6. Glaspy J, Davis MW, Parker WR, Foote M, McNiece I. Biology and clinical potential of stem cell factor. Cancer Chemother Pharmacol. 1996;38:s53-57.
7. Nelson WE, Behrman RE, Kliegman RM, Arvin AM, eds. Iron poisoning. In: Textbook of Pediatrics. Philadelphia, Pa: Saunders; 1996:2019
8. Bishop MR, Tarantalo SR, Jackson JD, et al. Allogeneic blood stem cell collection following mobilization with low dose granulocyte colony stimulating factor. J Clin Oncol. 1997;15:1601-1607.
9. Seong C, Durett A, Mirza N, Huh Y, Anderlini P, Champlin R. Mobilization kinetics of CD34+/Thy-1 dim progenitor cells during recombinant human granulocyte-colony-stimulating factor administration in normal donors. Transfusion. 1997;37:406-410.
10. Stroncek DR, Clay ME, Petzoldt ML, et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996;36:601-610.
11. Anderlini P, Przepriorka D, Seong D, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem apheresis from normal donors, and analysis of charges for the procedures. Transfusion. 1996;36:590-595.
12. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993;81:1883-1888.
13. Hester JP, Dignani MC, Anaissie EJ, Kantarjian HM, O'Brien S, Freireich EJ. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.; Clin Apheresis. 1995;10:188-193.
14. Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filigrastim (granulocyte-colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood. 1995;86:4437-4445.
15. Stroncek DF, Clay ME, Smith J, llstrup S, Oldham F, McCullough J. Changes in blood counts after the administration of granulocyte-colony-stimulating factor and the collection of peripheral blood stem cells from healthy donors. Transfusion. 1996;36:596-600.
16. Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol. 1994;88:723-730.
17. Marinez C, Urbano-lspizua A, Rozman C, et al. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol. 1996;72:269-272.
18. Matsumura T, Maruyama-Tabata H, Kuwahara Y, Sawada T, Ikeda T. Subretinal hemorrhage after granulocyte colony-simulating factor. Lancet. 1997;350:336.
19. Parkkali T, Volin L, Siren M-K, Ruutu T. Case report: acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplant. 1996;17:433-434.
20. Hoekman K, von Blomberver der Flier BME, Wagstaff J, Drexhage HA, Pinedo HM. Reversible thyroid dysfunction during treatment with GM-CSF. Lancer. 1991;338:541-542.